{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5fa6e74a24d4fb37ae007c6d/622774fb6f48ef00123407b0?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Steroids, Dyspnea, and COVID: Clinical Challenges in COPD Management","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/5fa6e74a24d4fb37ae007c6d/1606931297957-5f396aa3836c0c97b71c5b6db20c63a7.jpeg?height=200","description":"<p>In early 2022, the state of the art for managing patients with COPD continues to present challenges. When, how, and in whom are inhaled steroids the most effective way to reduce exacerbations? Are the GOLD guidelines still relevant? What do patients with COPD need to know about the dangers and long-term effects of COVID-19 infection?&nbsp;&nbsp;</p><p>These are some of the questions we discuss with our guest, Dr. Nirupama Putcha from the Division of Pulmonology and Critical Care at the Johns Hopkins University School of Medicine, in this issue of&nbsp;<em>e</em>Pulmonology Review.&nbsp;</p><p><br></p><p>Take our&nbsp;<a href=\"https://elit.dkbmed.com/issues/128/test\" rel=\"noopener noreferrer\" target=\"_blank\">post-test</a>&nbsp;to claim CME credits.</p>","author_name":"ePulmonology Review"}